Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

Pau, Enrique Carrillo de Santa; Arias, F.; Peláez, E. Caso; Trueba, Ignacio Muguruza; Hernández, Ignacio Sánchez; Muñoz-Molina, Gemma María; Balsalobre, Ramón Moreno; Sacristán, Silvia; Gómez-Pinillos, Alejandro; Lobo, María del Val Toledo

doi:10.3109/07357900903405900

Cited by 17 publications

(9 citation statements)

References 35 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum levels of KL-6 or VEGF were reported to be increased in patients with IPF but also in lung cancer patients [25,26]. The production of SP-A and SP-D by lung adenocarcinoma cells obtained from malignant pleural effusions has also been previously reported [27].…”

Section: Discussionmentioning

confidence: 90%

The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D

et al. 2012

View full text Add to dashboard Cite

BackgroundNapsin A, an aspartic protease, is mainly expressed in alveolar type-II cells and renal proximal tubules and is a putative immunohistochemical marker for pulmonary adenocarcinomas. This study sought to determine whether napsin A could be measured in the serum to evaluate its relationship to idiopathic pulmonary fibrosis (IPF) and determine whether renal dysfunction might affect serum napsin A levels.MethodsSerum levels of napsin A were measured in 20 patients with IPF, 34 patients with lung primary adenocarcinoma, 12 patients with kidney diseases, and 20 healthy volunteers. Surfactant protein (SP)-A, SP-D, and Krebs von den Lungen-6 (KL-6) levels in serum and pulmonary function tests were also evaluated in IPF patients.ResultsCirculating levels of napsin A were increased in patients with IPF, as compared with healthy controls, and they correlated with the severity of disease. Moreover, the serum napsin A levels were not elevated in patients with pulmonary adenocarcinoma or renal dysfunction. The distinguishing point between IPF and the controls was that the area under the receiver operating characteristic curve (ROC) of napsin A was larger than that of KL-6, SP-A, or SP-D.ConclusionThese findings suggest that serum napsin A may be a candidate biomarker for IPF.

show abstract

Section: Discussionmentioning

confidence: 90%

The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D

et al. 2012

View full text Add to dashboard Cite

show abstract

“…This may be a confounding factor in the investigations into KL-6 as a biomarker for prognosis of IPF, as IPF itself is associated with an increased incidence of lung cancer, raising the question whether the correlation between increased levels of KL-6 and a worse prognosis of IPF patients is partly due to an increase in lung cancer [78][79][80]. Similarly, serum VEGF levels were not only reported to be increased in advanced stages of pulmonary fibrosis, but also significantly increased in lung cancer patients [81].…”

Section: Discussionmentioning

confidence: 99%

Serum biomarkers in idiopathic pulmonary fibrosis

Blink

Wijsenbeek

Hoogsteden

2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…Breast and gynecologic cancer are among the best known malignancies that use lymphangiogenesis, the recruitment of blood and lymphatic vessels, to a growing tumor [22]. It was confirmed by other studies that VEGF plays an important role in the development of breast [23], reproductive organ [24-26] and ovarian cancer [27,28] as well as lung [29], colon [30], and gastric [31] cancer.…”

Section: Introductionmentioning

confidence: 98%

The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors

et al. 2013

View full text Add to dashboard Cite

BackgroundVEGF may play a role in the pathogenesis of cancer disease, for example in cell growth, proliferation and angiogenesis. In this study, we investigated plasma levels of this cytokine in comparison to plasma levels of a new biomarker - HE4 and the established tumor marker CA125 in ovarian cancer patients (100) as compared to control groups: patients with a benign ovarian tumor (80) and healthy subjects (50).MethodsPlasma levels of VEGF were determined by ELISA, HE4 and CA125 by CMIA method.ResultsThe results showed that levels of VEGF, CA125 and HE4 were significantly higher in ovarian cancer (OC) patients as compared to the both control groups. VEGF has demonstrated as high as comparative markers values of the diagnostic sensitivity (SE), specificity (SP), the predictive values of positive and negative test results (PV-PR, PV-NR), and the area under the ROC curve (AUC) in early stages of cancer tested groups. The combined use of parameters studied resulted in the increase in the diagnostic criteria values and the AUC.ConclusionsThese findings suggest the usefulness of VEGF in the early diagnostics of ovarian cancer, especially in combination with CA125 and HE4, as a new biomarkers panel. Additionally, VEGF is the most useful tool in the diagnostics of locally advanced ovarian cancer without metastases. Investigated cytokine presented similar to HE4 usefulness in differentiation of OC according to its histopathlogical sub-type, and could be used especially in the diagnostics of endometrioid epithelial OC.

show abstract

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

Abstract: Elevated VEGF serum levels have a negative prognostic impact on survival in NSCLC and early stages of lung cancer patients.

Cited by 17 publications

References 35 publications

The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D

The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D

Serum biomarkers in idiopathic pulmonary fibrosis

The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors

Contact Info

Product

Resources

About